Jubilant Ingrevia Acquires Remidex Pharma for ₹16.5 Crore

Jubilant Ingrevia Limited, a global integrated life science products company, has agreed to acquire 100% of Remidex Pharma Private Limited for ₹16.50 crore. The transaction is expected to conclude within 30 days.

Remidex Pharma reported a turnover of ₹31.15 crore in FY23-24 and ₹24.27 crore in FY24-25. The company specializes in manufacturing micronutrient premixes and operates as a contract manufacturer for pharmaceutical and healthcare products, placing it within the nutraceuticals space.

Strengthening the Nutrition Segment

This acquisition is set to significantly boost Jubilant Ingrevia's Human Nutrition segment. It aims to leverage the company's existing leadership in key vitamins, including Vitamin B3 (Niacinamide) and Vitamin B4 (Choline Chloride). By acquiring Remidex, Jubilant Ingrevia intends to move further up the value chain in health and wellness ingredients.

Strategic Alignment

Jubilant Ingrevia, which operates across Specialty Chemicals, Nutrition, and Life Science Chemicals, has signaled a strategic focus on expanding its Nutrition and Specialty Chemicals businesses. This approach includes both organic growth and strategic inorganic opportunities. The Remidex Pharma acquisition fits this strategy by adding complementary capabilities through a bolt-on acquisition.

Operational Impact and Investor Watchlist

The deal will give Jubilant Ingrevia control over Remidex Pharma's manufacturing facilities and its product portfolio in micronutrient premixes and nutraceuticals. This integration is expected to enhance Jubilant's offerings in the human nutrition market and potentially expand its contract manufacturing services.

The acquisition is subject to customary closing conditions. Investors will be watching the integration progress closely. A key focus will be Remidex Pharma's ability to reverse its recent turnover decline following the acquisition.

Market Context

Jubilant Ingrevia's peers in the specialty chemicals sector include companies like Aarti Industries Ltd. and Deepak Nitrite Ltd. These companies are also expanding capacities and portfolios in high-margin segments, reflecting a broader trend towards value-added products in India's chemical industry. While direct competitors in nutraceutical ingredients are fewer, Jubilant's move highlights the sector's attractiveness.